AMSTERDAM–(BUSINESS WIRE)–Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announced the signature of a license and option agreement with ProfoundBio, an emerging oncology biotherapeutics company. The deal provides access to multiple novel linker-payload technologies developed by Synaffix and includes access to the GlycoConnect(TM) glycan conjugation an